These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8133452)

  • 1. Prophylactic zalcitabine and interferon-alpha for a large-bore needlestick exposure to human immunodeficiency virus.
    Mildvan D; Bergé P; Starrett S; St Clair M; Salgo M
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):416-7. PubMed ID: 8133452
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of emergence of viral resistance on HIV treatment choice.
    Moyle G
    Int J STD AIDS; 1995; 6(3):225-6. PubMed ID: 7647133
    [No Abstract]   [Full Text] [Related]  

  • 3. [What should be done after needlestick injuries with possible HIV exposure?].
    Marcus U
    Fortschr Med; 1996 Feb; 114(4):23-4. PubMed ID: 8852682
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anti-HIV therapy (1987-1994): from nothing to confusion].
    Lissen E
    Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinicians experiment with post-exposure drug pairs.
    AIDS Alert; 1996 Feb; 11(2):16-7. PubMed ID: 11363233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
    Erice A; Balfour HH
    Clin Infect Dis; 1994 Feb; 18(2):149-56. PubMed ID: 7512829
    [No Abstract]   [Full Text] [Related]  

  • 7. Post-exposure prophylaxis for HIV.
    Gathiram V
    S Afr Med J; 2000 Apr; 90(4):346-51. PubMed ID: 10957915
    [No Abstract]   [Full Text] [Related]  

  • 8. Current perspectives on antiretroviral therapy.
    Fletcher CV
    Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.
    Fischl MA; Richman DD; Saag M; Meng TC; Squires KE; Holden-Wiltse J; Meehan PM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Dec; 16(4):247-53. PubMed ID: 9402071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
    Kamali F
    Clin Investig; 1993 May; 71(5):392-405. PubMed ID: 7685214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Needlestick transmission of hepatitis C.
    Sulkowski MS; Ray SC; Thomas DL
    JAMA; 2002 May; 287(18):2406-13. PubMed ID: 11988061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV therapy advances. Pediatric antiretroviral choices.
    Spector SA
    AIDS; 1994 Sep; 8 Suppl 3():S15-8. PubMed ID: 7840911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
    Pépin JM; Simon F; Brun-Vezinet F
    Pathol Biol (Paris); 1993 Oct; 41(8 Pt 2):788-93. PubMed ID: 8309722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
    Richman DD; Meng TC; Spector SA; Fischl MA; Resnick L; Lai S
    J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):135-8. PubMed ID: 7905522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy prevents HIV but not HCV transmission after needlestick injury.
    Fabris P; Manfrin V; Rassu M; Tositti G; de Lalla F; Zanetti A
    Am J Gastroenterol; 1999 Jul; 94(7):1990-1. PubMed ID: 10406288
    [No Abstract]   [Full Text] [Related]  

  • 18. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accidental HIV exposure.
    Abayomi EA; Mandisodza MT
    Cent Afr J Med; 1998 Feb; 44(2):44-5. PubMed ID: 9675972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.